Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.07
-0.10 (-0.98%)
At close: May 1, 2026, 4:00 PM EDT
10.18
+0.11 (1.11%)
After-hours: May 1, 2026, 7:59 PM EDT
Zevra Therapeutics Revenue
In the year 2025, Zevra Therapeutics had annual revenue of $106.47M with 350.91% growth. Zevra Therapeutics had revenue of $34.13M in the quarter ending December 31, 2025, with 183.36% growth.
Revenue (ttm)
$106.47M
Revenue Growth
+350.91%
P/S Ratio
5.59
Revenue / Employee
$1,745,410
Employees
61
Market Cap
595.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.47M | 82.86M | 350.91% |
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.00M | 162.58% |
| Dec 31, 2022 | 10.46M | -18.19M | -63.50% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | 12.84M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Arvinas | 262.60M |
| Sutro Biopharma | 102.48M |
| Crescent Biopharma | 11.88M |
| Prothena Corporation | 9.68M |
| Aclaris Therapeutics | 7.83M |
| Adlai Nortye | 5.00M |
| Prime Medicine | 4.63M |
ZVRA News
- 6 weeks ago - Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Zevra Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Present at the Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp